Allergan Stock Buy Or Sell Official
As of April 2026, . The company was acquired by AbbVie (NYSE: ABBV) in a $63 billion deal that officially closed on May 8, 2020.
Because Allergan has been integrated into AbbVie, you can no longer buy or sell "AGN" shares directly. Instead, investors seeking exposure to Allergan's former portfolio—including and Juvederm —must now trade AbbVie stock. Investment Profile for AbbVie (ABBV)
: The Allergan division, now branded as Allergan Aesthetics , continues to lead the global medical aesthetics market with products like Botox.
: AbbVie is a known "Dividend King," having consistently increased its dividend for over 50 consecutive years.
Since the acquisition, AbbVie has used Allergan’s aesthetics and neuroscience portfolios to diversify its revenue.
: Analysts are currently focused on AbbVie's ability to offset the loss of exclusivity for its flagship drug, Humira, through newer immunology drugs like Skyrizi and Rinvoq .
If you previously held Allergan (AGN) shares, they were converted during the 2020 merger according to the following terms: AbbVie Completes Transformative Acquisition of Allergan
: For the full year 2026, management has guided for net revenues of approximately $67 billion, representing 9.5% growth. Historical Acquisition Terms
As of April 2026, . The company was acquired by AbbVie (NYSE: ABBV) in a $63 billion deal that officially closed on May 8, 2020.
Because Allergan has been integrated into AbbVie, you can no longer buy or sell "AGN" shares directly. Instead, investors seeking exposure to Allergan's former portfolio—including and Juvederm —must now trade AbbVie stock. Investment Profile for AbbVie (ABBV)
: The Allergan division, now branded as Allergan Aesthetics , continues to lead the global medical aesthetics market with products like Botox.
: AbbVie is a known "Dividend King," having consistently increased its dividend for over 50 consecutive years.
Since the acquisition, AbbVie has used Allergan’s aesthetics and neuroscience portfolios to diversify its revenue.
: Analysts are currently focused on AbbVie's ability to offset the loss of exclusivity for its flagship drug, Humira, through newer immunology drugs like Skyrizi and Rinvoq .
If you previously held Allergan (AGN) shares, they were converted during the 2020 merger according to the following terms: AbbVie Completes Transformative Acquisition of Allergan
: For the full year 2026, management has guided for net revenues of approximately $67 billion, representing 9.5% growth. Historical Acquisition Terms